Bispecific monoclonal antibody

This page covers all Bispecific monoclonal antibody drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting HER2 and HER3, PD-1/LAG-3 (AK117) and PD-L1/TIM-3 (AK112), EGFR and MET.

Targets

HER2 and HER3 · PD-1/LAG-3 (AK117) and PD-L1/TIM-3 (AK112) · EGFR and MET · VEGF and HER2 · CD19 and CD3

Phase 3 pipeline (7)

• GST-HG141 · Fujian Akeylink Biotechnology Co., Ltd. · Oncology
  GST-HG141 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T-cell responses.
• BAT8001 for injection · Bio-Thera Solutions · Oncology
  BAT8001 is a bispecific antibody that simultaneously engages tumor-associated antigens and immune effector cells to enhance anti-tumor immunity.
• KN026 · Shanghai JMT-Bio Inc. · Oncology
  KN026 is a bispecific antibody that simultaneously binds to HER2 and HER3 receptors to block their signaling pathways in cancer cells.
• SHR-A2009 monotherapy · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Oncology
  SHR-A2009 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T-cell responses.
• AK117 in combination with AK112 · Akeso · Oncology
  AK117 and AK112 are bispecific antibodies that simultaneously engage immune checkpoint pathways to enhance anti-tumor T-cell responses.
• Amivantamab Intravenous · Janssen Research & Development, LLC · Oncology
  Amivantamab is a bispecific monoclonal antibody that simultaneously binds to EGFR and MET receptors, blocking their signaling and triggering immune-mediated tumor cell death.
• VB4-845 Injection · Qilu Pharmaceutical Co., Ltd. · Oncology
  VB4-845 is an anti-VEGF/HER2 bispecific antibody that simultaneously targets vascular endothelial growth factor and human epidermal growth factor receptor 2 to inhibit tumor angiogenesis and block HER2-driven proliferation.

Phase 2 pipeline (1)

• Blinatumomab plus Reduced-dose Chemotherapy · Xianmin Song, MD · Oncology
  Blinatumomab targets CD19 and CD3 on T cells, leading to T cell activation and killing of B cell malignancies.